Jenscare Scientific Co., Ltd. is a medical device company specializing in the research, development, manufacturing, and commercialization of innovative minimally invasive interventional therapies for structural heart diseases. Founded in November 2011 and headquartered in Ningbo, China, the company offers core products including the LuX-Valve series, a transcatheter tricuspid valve replacement system for severe tricuspid regurgitation; the Ken-Valve, designed for severe aortic regurgitation and combined aortic stenosis; the JensClip, a clip-based transcatheter mitral valve repair system for mitral regurgitation; the JensRelive transfemoral TMVR system; and the SimuLock left atrial appendage occluder for cardiogenic stroke prevention. Jenscare targets global markets and conducts clinical trials and commercialization preparations across regions including China, the U.S., and Europe. Major recent developments include advancing global commercialization of LuX-Valve Plus with significant clinical data release and ongoing registration trials internationally, the approval of Ken-Valve registration by China's National Medical Products Administration in early 2025, and the release of positive mid- and long-term clinical outcomes for their product portfolio. The company has demonstrated narrowing net losses and strong cash positions to support commercialization efforts and R&D activities. Jenscare continues expanding its product pipeline to address a broad spectrum of structural heart diseases and improve access to effective treatments globally.